Research priority: Eliminate complications Together, we can progress towards eliminating diabetes complications Diabetes increases the risk of multiple chronic and acute complications, such as cardiovascular disease, kidney disease and failure, vision loss, nerve damage, limb amputation, and psychosocial health challenges. This priority area supports research that leads to greater understanding, care models, and prevention strategies.  Research to more fully understand and ameliorate the physical and psychosocial complications of diabetes is helping to optimise long-term health outcomes and quality of life. Featured research projects Optimising and individually tailoring medication for individual needs Find out more about our research Featured research projects Our research focus covers a broad range of diabetes-related complications, including, but not limited to: Early detection approaches and intervention strategies that will help prevent or slow the progression of complications. Innovative treatments for nerve damage, eye disease, kidney disease, and cardiovascular risk. Integrated care models, combining physical interventions with mental and emotional wellbeing support. Technologies and tools to improve monitoring and personalised support. Ongoing research into the biological pathways that link diabetes to other chronic conditions. Optimising and individually tailoring medication for individual needs Professor Karen Jones Challenge Postprandial hypotension (PPH) is an important, but still poorly appreciated, clinical disorder characterised by a substantial fall in blood pressure after meals. PPH occurs frequently in people with type 2 diabetes (~25 to 40%) and can lead to fainting, falls, stroke and angina, and thereby affect quality of life adversely. There is currently no effective treatment for PPH. Professor Karen Jones, a Senior Research Fellow, with a background in nuclear medicine at Adelaide University, is funded by ºÚÁÏÍø to extend her research in this area. While the pathophysiology of PPH has been poorly defined, Professor Jones and her research team have shown that the fall in blood pressure after a meal is greater when the rate at which the stomach empties food is relatively faster. Bold idea A widely used glucose-lowering medication, the GLP-1 receptor agonist, semaglutide sc, may slow stomach emptying. However, most research in this area has not used the ‘gold standard’ nuclear medicine technique to measure stomach emptying. Slowing stomach emptying is also likely to contribute to the potent effects of semaglutide sc to reduce blood sugar levels after meals and diminish appetite – this effect also has the potential to reduce the magnitude of the fall in blood pressure following meals. Impact A better understanding of the effects of semaglutide sc on stomach emptying in people living with type 2 diabetes may establish its potential as a treatment for PPH and improve understanding relevant to the more personalised and effective use of this medication, including in relation to procedures which require fasting, such as surgery and endoscopy. Learn more about ºÚÁÏÍø research Our research impact Discover how your investment in Australian research is changing the landscape of diabetes management, treatment, and prevention globally. Learn more Research grants and funding opportunities We provide funding opportunities to advance scientific knowledge and its translation into evidence-based solutions. Learn more Our strategy and priorities Successful research outcomes rely on a unified approach from everyone who wants to see a world free of diabetes. Learn more
Our research impact Discover how your investment in Australian research is changing the landscape of diabetes management, treatment, and prevention globally. Learn more
Research grants and funding opportunities We provide funding opportunities to advance scientific knowledge and its translation into evidence-based solutions. Learn more
Our strategy and priorities Successful research outcomes rely on a unified approach from everyone who wants to see a world free of diabetes. Learn more